Doctor-led aesthetics in Sutton Coldfield
MDr MaryamAesthetics

Polynucleotides

Polynucleotides for crow’s feet: how a retraction changes the evidence

A recent review found encouraging short-term results for periorbital polynucleotides, but one large trial was subsequently retracted, changing how confidently the evidence should be described.

5 minute read

Crow’s feet have more than one component

Crow’s feet are lines beside the eyes. They may appear mainly during smiling, remain visible at rest or sit alongside dryness, sun-related change and loss of skin elasticity. Deeper structural hollowing under the eye is a different concern. A treatment aimed at skin quality cannot be expected to correct every cause of an ageing eye area.

Polynucleotide injections are studied for gradual changes in fine lines and measures such as hydration, elasticity and texture. They do not switch off facial expression and are not a substitute for structural volume correction. Consultation should therefore identify whether the priority is movement-related lines, skin quality, pigmentation, puffiness, hollowing or a combination before treatment is proposed.

What did the 2026 systematic review report?

A 2026 systematic review identified six studies of injectable polynucleotides around the eyes: five split-face randomised trials and one prospective case series, with 350 participants in total. Studies reported short-term improvement in crow’s-feet severity or skin-quality measurements, but used different products, comparators, schedules, injection techniques and outcomes, so the authors did not combine them in a meta-analysis.

The review described 40% to 70% of treated sides achieving at least a one-grade improvement at 12 weeks across different trials. That range is not one pooled success rate and should not be presented as an individual probability. All studies were conducted in Korean or Thai cohorts, mostly middle-aged women with Fitzpatrick III–V skin, and none followed participants beyond six months.

Why a later retraction matters

One study in the review involved more than 200 participants and compared PN with another injectable material. The journal later retracted the paper after the authors reported that the comparator had been misidentified. The retraction notice states that the materials had different properties and that the error undermined the reliability of the reported methods and findings.

A retracted paper should not continue to support claims of comparative effectiveness. Because this was the largest study in a review totalling 350 participants, quoting the review’s total sample without explaining the retraction would give a misleading impression of the current evidence. Reviews are valuable snapshots, but they need reappraisal when an included study is withdrawn.

What evidence remains?

A smaller randomised split-face trial enrolled 27 people and compared PN with non-cross-linked hyaluronic acid around the eyes. Overall aesthetic ratings were not significantly different between sides. Some elasticity, hydration, roughness and pore measurements favoured PN, while dermal-density improvement did not differ significantly. The study was small and involved three sessions at two-week intervals.

A 2026 prospective series of 42 patients reported better lower-eyelid and crow’s-feet questionnaire scores for up to six months, with the greatest satisfaction at three months after two sessions. However, it had no untreated or alternative-treatment control, so natural variation, expectation and other influences cannot be separated confidently from treatment. These studies support further research rather than a guaranteed result or standard course.

Downtime and adverse effects

Periocular injections can cause stinging, tenderness, redness, swelling, itching, small raised points, pinpoint bleeding and bruising. Temporary puffiness may be more noticeable in an area already prone to fluid retention. Small trials and short follow-up cannot reliably identify uncommon or delayed reactions, particularly after repeated treatment courses.

Increasing pain, spreading redness or heat, discharge, fever, marked or persistent swelling, firm or enlarging lumps, unusual pale or mottled skin, eye pain, double vision or any visual change needs prompt clinical assessment. Sterile technique, an authentic traceable product, written aftercare and access to timely review are essential.

Suitability and consent must reflect current evidence

Consultation should assess the lines at rest and during expression, eyelid and tear-trough anatomy, puffiness, skin condition and realistic goals. Medical conditions, medicines, allergies including fish allergy where relevant, pregnancy or breastfeeding, active infection or inflammation and previous reactions must be reviewed. Another treatment, skincare, sun protection or no procedure may be more appropriate.

A responsible discussion explains that current evidence is small, short-term and less certain after the retraction. It should cover likely subtle change, alternatives, treatment burden, downtime, total cost and follow-up. GMC guidance requires accurate information, realistic expectations and up-to-date evidence; withdrawn research should be removed from promotional claims rather than quietly left in the headline figures.

← Back to the journal

Personalised medical assessment

Questions about treatment?

Book a consultation to discuss your concerns, health and treatment options without pressure.

Free consultation – a £1 booking fee secures your appointment